HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Rebleeding after initial endoscopic hemostasis in peptic ulcer disease.

Abstract
Endoscopic hemostasis is the first-line treatment for upper gastrointestinal bleeding (UGIB). Although several factors are known to be risk factors for rebleeding, little is known about the use of antithrombotics. We tried to verify whether the use of antithrombotics affects rebleeding rate after a successful endoscopic hemostasis for peptic ulcer disease (PUD). UGIB patients who underwent successful endoscopic hemostasis were included. Rebleeding was diagnosed when the previously treated lesion bled again within 30 days of the initial episode. Of 522 UGIB patients with PUD, rebleeding occurred in 93 patients (17.8%). The rate of rebleeding was higher with aspirin medication (P=0.006) and after a long endoscopic hemostasis (P<0.001). Of all significant variables, procedure time longer than 13.5 min was related to the rate of rebleeding (OR, 2.899; 95% CI, 1.768-4.754; P<0.001) on the logistic regression analysis. The rate of rebleeding after endoscopic hemostasis for PUD is higher in the patients after a long endoscopic hemostasis. Endoscopic hemostasis longer than 13.5 min is related to rebleeding after a successful endoscopic hemostasis for PUD.
AuthorsMi Jin Hong, Sun-Young Lee, Jeong Hwan Kim, In-Kyung Sung, Hyung Seok Park, Chan Sup Shim, Choon Jo Jin
JournalJournal of Korean medical science (J Korean Med Sci) Vol. 29 Issue 10 Pg. 1411-5 (Oct 2014) ISSN: 1598-6357 [Electronic] Korea (South)
PMID25368496 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antithrombins
  • Aspirin
Topics
  • Antithrombins (therapeutic use)
  • Aspirin (adverse effects)
  • Female
  • Gastrointestinal Hemorrhage (drug therapy, surgery)
  • Hemorrhage (drug therapy)
  • Hemostasis, Endoscopic (methods)
  • Humans
  • Male
  • Middle Aged
  • Peptic Ulcer (surgery)
  • Recurrence
  • Upper Gastrointestinal Tract (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: